Ziyuglycoside I is a natural triterpenoid found in the roots of Sanguisorba officinalis, it exhibits the activity of anti-inflammatory, and so it could be used as an active ingredient for cosmetics.

Ziyuglycoside II, a natural triterpenoid found in the roots of Sanguisorba officinalis.it has a wide range of clinical applications including hemostasis, antibiosis,anti-inflammation and anti-oxidation and also has inhibitory effect on the growth ofMDA-MB-435 cells, which may become a potential therapeutic approach of breast cancer in the future. Ziyuglycoside II methyl ester has improved anti-diabetic properties.

ZJ 43 is a potent inhibitor of glutamate carboxypeptidase II and III (GCP II and III/NAAG peptidase/NAALADase) (Ki = 0.8 and 23 nM, respectively). It inhibits the hydrolysis of NAAG (IC50 = 2.4 nM) and decreases the deleterious effects of excessive extracellular glutamate. ZJ 43 has been shown to reduce neuronal degeneration in a rat […]

ZK 164015 is a potent estrogen receptor (ER) silent antagonist. ZK 164015 inhibits 17β-estradiol stimulation of luciferase activity (IC50 = 0.025 μM), and inhibits the growth of estrogen-sensitive human MCF-7 breast cancer cells in vitro (IC50 ~ 1 nM).

Selective, non-peptide CCR8 agonist

ZK 93423 hydrochloride is a potent and non-selective benzodiazepine receptor agonist (IC50 = 1 nM) (Ki = 4.1, 4.2, 6 and 4.5 nM for inhibition of [3H]Ro15-1788 binding to human recombinant α1β3γ2, α2β3γ2, α3β3γ2 and α5β3γ2 receptors, respectively). ZK 93423 hydrochloride acts as an anxiolytic following systemic administration in vivo.

ZK 93426 hydrochloride is a potent, selective and competitive benzodiazepine receptor antagonist (IC50 = 0.4 and 0.7 nM for inhibition of [3H]-flunitrazepam binding to rat cerebellum and hippocampus, respectively). ZK 93426 hydrochloride displays both anxiogenic and anxiolytic effects.

ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC50 of 5 nM for VEGFR2. The high efficacy, including tumour regression in established tumours, combined with its low toxicity recommends ZK 261991 for development as a drug for the therapy of solid tumours also in combination with other chemotherapeutics.

ZK 304709 is a oral multitarget tumour growth inhibitor inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.

ZK-90055, a β-Adrenoceptor agonist, is a B-2 bronchodilator drug.

ZK-Thiazolidinone, also known as TAL, is an ATP-competitive inhibitor of PLK1. In vitro, ZK-Thiazolidinone counteracts the role of Plk1 in previously established functions, notably, sister chromatid separation, centrosome maturation, and bipolar spindle assembly.

ZK118182 is a prostaglandin (PG) analog that exhibits potent DP-agonist activity (EC50 = 16.5 nM) and a high nanomolar affinity for the DP receptor (Ki = 74 nM).

Competitive AMPA/kainate antagonist. In rat cortical membranes, displays high affinity for [3H]-AMPA (Ki = 120 nM) and [3H]-CNQX (Ki = 32 nM) binding sites and low affinity for kainate and NMDA channel-associated binding sites (IC50 values range from 2.5 to 11 μM). Inhibits currents induced by AMPA, kainate and NMDA with IC50 values of 21 […]

ZK200775 hydrate(Fanapanel; MPQX) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.

ZK756326 is a selective and nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8 (IC50= 1.8 muM).

ZL006 is a potent inhibitor of nNOS/PSD-95 interaction. And in mice subjected to mCao and reperfusion, pretreatment with Zl006attenuated the ischemia-induced increase in nnos-PsD-95 complex levels, and in neurons treated with glutamate this drug ameliorated nmDar-dependent nitric oxide synthesis.

ZLD1039 potent, highly selective, and orally bioavailable small molecule inhibitor of EZH2, which inhibited the methyltransferase activity of EZH2 with high selectivity across an HMT panel. Treatment of xenograft-bearing mice with ZLD1039 led to tumor growth regression and metastasis inhibition, confirmed the dependency of breast cancer progression on EZH2 activity and the usefulness of ZLD1039 […]

ZLJ-6 is a dual inhibitor of COX and 5-lipoxygenase (5-LO) with IC50 values of 0.73, 0.31, and 0.99 μM for COX-1, COX-2, and 5-LO, respectively. It reduces carrageenin-induced paw edema (inflammation) in rats and acetic acid-induced abdominal constriction (pain) in mice without causing gastrointestinal ulcers, a common side effect of non-selective COX inhibitors.

Selective transcriptional regulator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α). ZLN005 selectively stimulated the expression of PGC-1α and downstream genes in skeletal muscle cells, and led to changes in glucose uptake, and fatty acid oxidation in L6 myotubes in a AMPK dependent manner. Since ZLN 005 did not increase the expression of the PGC-1α gene in […]

ZLN024 is a novel AMPK allosteric activator and activates α1β1γ1 and α2β1γ1 by around 2-2.5 fold. It activated AMPK in L6 myotubes and stimulated glucose uptake and fatty acid oxidation without increasing the ADP/ATP ratio. It also activated AMPK in primary hepatocytes, decreased fatty acid synthesis and glucose output.

ZM 226600 is a potent Kir6 (KATP) channel opener (EC50 = 0.5 μM) devoid of antiandrogen properties.

Potent, highly selective A2A antagonist

ZM 260384, a benzoxazine derivative, has been found to be a potassium channel agonist that was once studied against hypertension and thrombus.

ZM 306416 hydrochloride is an inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinase with > 3-fold selectivity over FGFR-1. ZM 306416 hydrochloride inhibits activity of KDR and FLT VEGF receptors (IC50 = 100 nM and 2 μM, respectively).

ZM 39923 inhibits Janus kinase (IC50=10 nM).

ZM 39923 HCl is a potent and selective inhibitor of JAK3, and also inhibits EGFR, JAK1 and CDK4. It breaks down in neutral buffer (t½ = 36 mins, pH 7.43, 25°C) to form ZM 449829.

ZM 39923 hydrochloride is a potent and selective inhibitor of Janus tyrosine kinase 3 (JAK3) (pIC50 = 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4, respectively). ZM 39923 breaks down in neutral buffer (t½ = 36 mins, pH 7.43, 25°C) to produce an active analog, ZM 449829.

ZM 449829 is a potent and selective inhibitor of Janus tyrosine kinase 3 (JAK3) which binds competitively to the JAK3 ATP site (pIC50 = 6.8, 5.0, 4.7, and < 5.0 for JAK3, EGFR, JAK1 and CDK4, respectively). ZM 449829 inhibits STAT-5 phosphorylation and T cell proliferation.

ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inflammatories and osteoporosis therapies.

ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist.

ZM323881 inhibits VEGF-A, EGF and bFEF induced HUVEC cell proliferation with IC50 of 8 nM, 1.9 μM and 1.6 μM, respectively. ZM323881 (10 nM) abolishes VEGF-A-mediated increases in vascular permeability in perfused mesenteric microvessels in male leopard. ZM323881 (10 nM) blocks the increase in intensity of the VEGF-R2 band in the lung of male leopard […]

Potent and selective inhibitor of VEGFR2 (IC50: 2 nM for VEGFR2 vs >50 mM for VEGFR1 respectively)

ZM336372 is a Raf-1 activating agent, has been shown to cause growth inhibition and suppression of hormone secretion in a neuroendocrine cell line. ZM336372 causes growth inhibition, suppression of hormone secretion, and up-regulation of cell cycle inhibitors in a human hepatocellular carcinoma cell line, similar to that previously seen in NETs.

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM, 130 nM respectively, > 8 fold selectivity than Aurora C

Zn-Nicotinamine is a Zn-coordinated Nicotianamine (N408500) which is a key element in plant metal homeostasis.

Zoalene-[Dinitolmide-d5] is the labelled analogue of Zoalene. Zoalene is a fodder additive used for prevention of coccidiosis infections.